Bortenat Bortezomib 2mg Injection

Product Description

Bortenat 2mg Injection is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Fatigue, nausea, vomiting, and loss of appetite are some common side effects of this medicine. You may be advised to drink plenty of fluids every day during the treatment. You should not drive or operate machinery as medicine may cause tiredness and dizziness. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels.

Before taking Bortenat 2mg Injection, consult with your doctor if you have any liver, kidney, heart disease or bleeding problem.  It is important to consult a doctor if you develop symptoms like memory loss or trouble in thinking. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Advanced Anticancer Therapy

Bortenat Bortezomib 2mg Injection, formulated and marketed by Natco Pharma Ltd., is indicated for the management of multiple myeloma and mantle cell lymphoma. Its active ingredient, Bortezomib, works as a proteasome inhibitor to interrupt cancer cell proliferation, offering hope for patients requiring advanced oncology care.


Simple and Secure Administration

This lyophilized powder injection requires careful reconstitution with sterile water before administration. Healthcare professionals administer it either intravenously or subcutaneously, ensuring accurate dosing and effective delivery. Single-vial packaging enhances handling and reduces contamination risks during preparation.


Quality and Safety Assured

Meeting WHO-GMP certification standards, Bortenat Bortezomib is manufactured for export quality, ensuring global benchmarks for efficacy and safety. The product's strict storage guidelines and secure packaging help maintain its stability and therapeutic effectiveness throughout its two-year shelf life.